{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Suspension",
    "query": {
      "intervention": "Placebo Suspension"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 539,
    "total_pages": 54,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Suspension&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-11T09:08:54.717Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00347555",
      "title": "Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Plasmodium Falciparum Malaria"
      ],
      "interventions": [
        {
          "name": "Aluminum Phosphate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "EBA-175 RII-NG Malaria Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 80,
      "start_date": "2006-05",
      "completion_date": "2008-04",
      "has_results": false,
      "last_update_posted_date": "2013-04-12",
      "last_synced_at": "2026-09-11T09:08:54.717Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00347555"
    },
    {
      "nct_id": "NCT02122198",
      "title": "Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cognitive Impairment",
        "Executive Dysfunction",
        "Endothelial Dysfunction",
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Leuprolide acetate",
          "type": "DRUG"
        },
        {
          "name": "Estradiol",
          "type": "DRUG"
        },
        {
          "name": "Medroxyprogesterone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 60 Years · Female only"
      },
      "enrollment_count": 17,
      "start_date": "2014-09-08",
      "completion_date": "2017-09-15",
      "has_results": true,
      "last_update_posted_date": "2022-01-10",
      "last_synced_at": "2026-09-11T09:08:54.717Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Boulder, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02122198"
    },
    {
      "nct_id": "NCT04847232",
      "title": "Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperkalemia"
      ],
      "interventions": [
        {
          "name": "Sodium Zirconium Cyclosilicate (SZC)",
          "type": "DRUG"
        },
        {
          "name": "SZC Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 2690,
      "start_date": "2021-04-30",
      "completion_date": "2024-03-07",
      "has_results": true,
      "last_update_posted_date": "2025-06-18",
      "last_synced_at": "2026-09-11T09:08:54.717Z",
      "location_count": 57,
      "location_summary": "Huntsville, Alabama • Mesa, Arizona • Bakersfield, California + 47 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04847232"
    },
    {
      "nct_id": "NCT00941486",
      "title": "FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Adenoviral Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "FST-100 Ophthalmic Suspension",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2009-06-30",
      "completion_date": "2010-06-30",
      "has_results": false,
      "last_update_posted_date": "2021-08-24",
      "last_synced_at": "2026-09-11T09:08:54.717Z",
      "location_count": 13,
      "location_summary": "Torrance, California • Colorado Springs, Colorado • Hamden, Connecticut + 10 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "North Miami Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00941486"
    },
    {
      "nct_id": "NCT07049159",
      "title": "Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Shigella"
      ],
      "interventions": [
        {
          "name": "ShigETEC vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Eveliqure Biotechnologies GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 72,
      "start_date": "2025-06-30",
      "completion_date": "2027-05-23",
      "has_results": false,
      "last_update_posted_date": "2025-07-08",
      "last_synced_at": "2026-09-11T09:08:54.717Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07049159"
    },
    {
      "nct_id": "NCT03503318",
      "title": "Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "TV-46000",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "13 Years to 65 Years"
      },
      "enrollment_count": 544,
      "start_date": "2018-04-27",
      "completion_date": "2020-12-03",
      "has_results": true,
      "last_update_posted_date": "2023-03-10",
      "last_synced_at": "2026-09-11T09:08:54.717Z",
      "location_count": 73,
      "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 58 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Colton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03503318"
    },
    {
      "nct_id": "NCT01954927",
      "title": "Pain Management in Children and Young Adults With Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Gabapentin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "1 Year to 20 Years"
      },
      "enrollment_count": 90,
      "start_date": "2013-10-07",
      "completion_date": "2018-01-03",
      "has_results": true,
      "last_update_posted_date": "2019-04-02",
      "last_synced_at": "2026-09-11T09:08:54.717Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01954927"
    },
    {
      "nct_id": "NCT02738450",
      "title": "Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Down Syndrome"
      ],
      "interventions": [
        {
          "name": "ACI-24 low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACI-24 high dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AC Immune SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "25 Years to 45 Years"
      },
      "enrollment_count": 20,
      "start_date": "2016-03",
      "completion_date": "2020-06",
      "has_results": true,
      "last_update_posted_date": "2021-10-15",
      "last_synced_at": "2026-09-11T09:08:54.717Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • La Jolla, California • Baltimore, Maryland + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02738450"
    },
    {
      "nct_id": "NCT02289482",
      "title": "A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "GSK2838232 PIB (SDD)",
          "type": "DRUG"
        },
        {
          "name": "GSK2838232 PIB (API)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2014-11-17",
      "completion_date": "2015-03-10",
      "has_results": false,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-09-11T09:08:54.717Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02289482"
    },
    {
      "nct_id": "NCT00324974",
      "title": "The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastroesophageal Reflux Disease"
      ],
      "interventions": [
        {
          "name": "Lansoprazole microgranules suspension",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "11 Months",
        "sex": "ALL",
        "summary": "1 Month to 11 Months"
      },
      "enrollment_count": 162,
      "start_date": "2006-06",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2010-07-22",
      "last_synced_at": "2026-09-11T09:08:54.717Z",
      "location_count": 9,
      "location_summary": "Tampa, Florida • Park Ridge, Illinois • Shreveport, Louisiana + 6 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Park Ridge",
          "state": "Illinois"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Flint",
          "state": "Michigan"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00324974"
    }
  ]
}